Bulk Manufacturer of Controlled Substances Application: Nanosyn, Inc., 48867-48868 [2018-21074]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 188 / Thursday, September 27, 2018 / Notices
Practice and Procedure (19 CFR part
210).
By order of the Commission.
Issued: September 21, 2018.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2018–21007 Filed 9–26–18; 8:45 am]
BILLING CODE 7020–02–P
JOINT BOARD FOR THE
ENROLLMENT OF ACTUARIES
Invitation for Membership on Advisory
Committee
Joint Board for the Enrollment
of Actuaries.
ACTION: Request for applications.
AGENCY:
The Joint Board for the
Enrollment of Actuaries (Joint Board),
established under the Employee
Retirement Income Security Act of 1974
(ERISA), is responsible for the
enrollment of individuals who wish to
perform actuarial services under ERISA.
To assist in its examination duties
mandated by ERISA, the Joint Board
established the Advisory Committee on
Actuarial Examinations (Advisory
Committee) in accordance with the
provisions of the Federal Advisory
Committee Act (FACA). The current
Advisory Committee members’ terms
expire on February 28, 2019. This notice
describes the Advisory Committee and
invites applications from those
interested in serving on the Advisory
Committee for the March 1, 2019–
February 28, 2021 term.
DATES: Applications for membership on
the Advisory Committee must be
received no later than December 7,
2018.
SUMMARY:
You may mail or deliver
applications to: Internal Revenue
Service; Joint Board for the Enrollment
of Actuaries; SE:RPO, Room 3422/IR,
Attn: Ms. Elizabeth Van Osten; 1111
Constitution Avenue NW, Washington,
DC 20224. Applications may also be
sent electronically to: nhqjbea@irs.gov.
See SUPPLEMENTARY INFORMATION for
application requirements.
FOR FURTHER INFORMATION CONTACT:
Elizabeth Van Osten, Designated Federal
Officer, at 202–317–3648.
SUPPLEMENTARY INFORMATION:
daltland on DSKBBV9HB2PROD with NOTICES
ADDRESSES:
1. Background
To qualify for enrollment to perform
actuarial services under ERISA, an
applicant must satisfy certain
experience and knowledge
requirements, which are set forth in the
Joint Board’s regulations. An applicant
VerDate Sep<11>2014
17:20 Sep 26, 2018
Jkt 244001
48867
may satisfy the knowledge requirement
through the successful completion of
Joint Board examinations in basic
actuarial mathematics and methodology
and in actuarial mathematics and
methodology relating to pension plans
qualifying under ERISA.
The Joint Board, the Society of
Actuaries, and the American Society of
Pension Professionals & Actuaries
jointly offer examinations acceptable to
the Joint Board for enrollment purposes
and which are acceptable to the other
two actuarial organizations as part of
their respective examination programs
members affiliated with any one
actuarial organization or employed with
any one firm.
Membership normally will be limited
to actuaries currently enrolled by the
Joint Board. However, individuals
having academic or other special
qualifications of particular value for the
Advisory Committee’s work will also be
considered for membership. Federallyregistered lobbyists and individuals
affiliated with Joint Board enrollment
examination preparation courses are not
eligible to serve on the Advisory
Committee.
2. Scope of Advisory Committee Duties
The Advisory Committee plays an
integral role in the examination program
by assisting the Joint Board in offering
examinations that enable examination
candidates to demonstrate the
knowledge necessary to qualify for
enrollment. The Advisory Committee’s
duties, which are strictly advisory,
include (1) recommending topics for
inclusion on the Joint Board
examinations, (2) reviewing and drafting
examination questions, (3)
recommending examinations, (4)
reviewing examination results and
recommending passing scores, and (5)
providing other recommendations and
advice relative to the examinations, as
requested by the Joint Board.
5. Member Designation
3. Member Terms and Responsibilities
Members are appointed for a 2-year
term. The upcoming term will begin on
March 1, 2019, and end on February 28,
2021. Members may seek reappointment
for additional consecutive terms.
Members are expected to attend
approximately 4 meetings each calendar
year and are reimbursed for travel
expenses in accordance with applicable
government regulations. In general,
members are expected to devote 125 to
175 hours, including meeting time, to
the work of the Advisory Committee
over the course of a year.
4. Member Selection
The Joint Board seeks to appoint an
Advisory Committee that is fairly
balanced in terms of points of view
represented and functions to be
performed. Every effort is made to
ensure that most points of view extant
in the enrolled actuary profession are
represented on the Advisory Committee.
To that end, the Joint Board seeks to
appoint several members from each of
the main practice areas of the enrolled
actuary profession, including small
employer plans, large employer plans,
and multiemployer plans. In addition,
to ensure diversity of points of view, the
Joint Board limits the number of
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
Advisory Committee members are
appointed as Special Government
Employees (SGEs). As such, members
are subject to certain ethical standards
applicable to SGEs. Upon appointment,
each member will be required to
provide written confirmation that he/
she does not have a financial interest in
a Joint Board examination preparation
course. In addition, each member will
be required to attend annual ethics
training.
6. Application Requirements
To receive consideration, an
individual interested in serving on the
Advisory Committee must submit (1) a
signed, cover letter expressing interest
in serving on the Advisory Committee
and describing his/her professional
qualifications, and (2) a resume and/or
curriculum vitae. Applications may be
submitted by regular mail, overnight
and express delivery services, and
email. In all cases, the cover letter must
contain an original signature.
Applications must be received by
December 7, 2018.
Dated: September 19, 2018.
Thomas V. Curtin, Jr.,
Executive Director, Joint Board for the
Enrollment of Actuaries.
[FR Doc. 2018–21001 Filed 9–26–18; 8:45 am]
BILLING CODE 4830–01–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Nanosyn, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
DATES:
E:\FR\FM\27SEN1.SGM
27SEN1
48868
Federal Register / Vol. 83, No. 188 / Thursday, September 27, 2018 / Notices
issuance of the proposed registration on
or before November 26, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on July 10,
2018, Nanosyn, Inc., 3331–B Industrial
Drive, Santa Rosa, California 95403–
2062 applied to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
SUPPLEMENTARY INFORMATION:
Controlled
substance
Drug code
Oxymorphone .......
Fentanyl ................
9652
9801
or objections to the issuance of the
proposed registration on or before
November 26, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW 8701
Morrissette Drive, Springfield, Virginia
22152.
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on August
27, 2018, Absolute Standards, Inc., 44
Rossotto Drive, Hamden, CT 06514
applied to be registered as a bulk
manufacturer for the basic classes of
controlled substances:
SUPPLEMENTARY INFORMATION:
Schedule
II
II
Controlled
substance
Drug code
Pentobarbital ........
The company is a contract
manufacturer. At the request of the
company’s customers, it manufactures
derivatives of controlled substance in
bulk form.
Dated: September 19, 2018.
John J. Martin,
Assistant Administrator.
2270
Schedule
II
The company plans to bulk
manufacture the listed controlled
substance for distribution to customers.
Dated: September 21, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–21075 Filed 9–26–18; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2018–21074 Filed 9–26–18; 8:45 am]
BILLING CODE 4410–09–P
daltland on DSKBBV9HB2PROD with NOTICES
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Federal Bureau of Investigation
Drug Enforcement Administration
[OMB Number: 1110–0068]
[Docket No. DEA–392]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Revision of a
Currently Approved Collection:
Records Modification Form (FD–1115)
Bulk Manufacturer of Controlled
Substances Application: Absolute
Standards, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic class, and applicants
therefore, may file written comments on
DATES:
VerDate Sep<11>2014
17:20 Sep 26, 2018
Jkt 244001
Criminal Justice Information
Services Division, Federal Bureau of
Investigation, Department of Justice.
ACTION: 60-Day notice.
AGENCY:
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
The Department of Justice
(DOJ), Federal Bureau of Investigation
(FBI), Criminal Justice Information
Services (CJIS) Division, will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
The proposed information collection is
published to obtain comments from the
public and affected agencies.
DATES: Comments are encouraged and
will be accepted for 60 days until
November 26, 2018.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Gerry Lynn Brovey, Supervisory
Information Liaison Specialist, FBI,
CJIS, Resources Management Section,
Administrative Unit, Module C–2, 1000
Custer Hollow Road, Clarksburg, West
Virginia 26306 (facsimile: 304–625–
5093) or email glbrovey@fbi.gov. Written
comments and/or suggestions can also
be sent to the Office of Management and
Budget, Office of Information and
Regulatory Affairs, Attention
Department of Justice Desk Officer,
Washington, DC 20503. Additionally,
comments may be submitted via email
to OIRA_submission@omb.eop.gov.
SUPPLEMENTARY INFORMATION: This
process is conducted in accordance with
5 CFR 1320.10. Written comments and
suggestions from the public and affected
agencies concerning the proposed
collection of information are
encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
SUMMARY:
E:\FR\FM\27SEN1.SGM
27SEN1
]]>Agencies
[Federal Register Volume 83, Number 188 (Thursday, September 27, 2018)]
[Notices]
[Pages 48867-48868]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-21074]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Nanosyn,
Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
[[Page 48868]]
issuance of the proposed registration on or before November 26, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on July
10, 2018, Nanosyn, Inc., 3331-B Industrial Drive, Santa Rosa,
California 95403-2062 applied to be registered as a bulk manufacturer
of the following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Oxymorphone.......................... 9652 II
Fentanyl............................. 9801 II
------------------------------------------------------------------------
The company is a contract manufacturer. At the request of the
company's customers, it manufactures derivatives of controlled
substance in bulk form.
Dated: September 19, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-21074 Filed 9-26-18; 8:45 am]
BILLING CODE 4410-09-P
